Compare Autodesk Inc (ADSK) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Autodesk Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Autodesk Inc trades at $209.23 (market cap $44.84B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $283.37 (market cap $7.85B). The key difference: Autodesk Inc is far larger — about 5.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | BIO | |
|---|---|---|
Market Cap | $44.84B | $7.85B |
Sector | Technology | Health |
52-Week High | $326.79 | $339.75 |
52-Week Low | $187.72 | $241.71 |
Enterprise Value | $44.64B | $7.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.
Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.
BIO trades at $292.50, down 1.47% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.58B for 2025 with net income of $759.90M, though it missed EPS estimates for three consecutive quarters. Positive cash flow from operations of $532.20M supports financial health, while recent news highlights Nasdaq compliance and industry participation.
Outlook remains cautiously optimistic with a consensus price target of $305.00, representing ~4% upside. Risks include consistent earnings misses and high P/E of 49.11, but strong analyst buy sentiment (53.85%) and improving profitability margins offer potential for recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
